Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation

2019

Supported by F. Hoffmann-La Roche, Ltd. (which was involved in study design, collection, analysis, and interpretation of the data).

Keywords:

Correction
Source
Cite
Save
Machine Reading By IdeaReader

10

References

6

Citations